AEON Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine. Trial did not meet primary endpoint$AEON Biopharma(AEON)$ 慢性偏头痛
| 发布于: | Android | 转发：0 | 回复：0 | 喜欢：0 |
AEON Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine. Trial did not meet primary endpoint$AEON Biopharma(AEON)$ 慢性偏头痛